MedPath

FDA and EMA feedback endorses vididencel registration trial preparations - FirstWord Pharma

Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

4DMT's 4D-150 Shows Promise in Wet AMD and DME, Advances to Phase 3 Trials

4DMT's 4D-150 demonstrates sustained delivery of anti-VEGF, reducing the need for frequent injections in wet AMD and DME patients.
SPECTRA trial data shows 4D-150 leads to significant visual acuity gains and CST reduction in DME, with FDA alignment for Phase 3.

Sweden's Mendus Clears Regulatory Path For Vididencel Registration Trial

Mendus, a Swedish company, has gained regulatory support from the FDA and EMA for pivotal studies of its allogenic leukemia-derived dendritic cell vaccine, Vididencel, following promising Phase II data presented at ASH.

FDA Approves Ribociclib for Adjuvant Treatment of Early Breast Cancer

The FDA has approved ribociclib for adjuvant treatment of early breast cancer, marking a significant advancement in patient care.
The approval is based on Phase 3 NATALEE trial results, which demonstrated the efficacy of ribociclib in this setting.

RevBio's Tetranite Bone Adhesive Trial Expanded Following FDA Nod, Gains CMS Reimbursement

RevBio received FDA approval to expand its clinical trial for Tetranite, a bone adhesive biomaterial, after demonstrating safety in initial patients.
The trial expansion allows Tetranite's use in intradural cases like tumor resection, beyond its initial extradural cranial flap fixation application.

FDA Reviewing RP1 and Nivolumab Combination for Advanced Melanoma After PD-1 Inhibitor Failure

The FDA is evaluating a biologics license application for RP1 plus nivolumab to treat advanced melanoma in adults who have previously received a PD-1 inhibitor.
The application is supported by data from the phase 1/2 IGNYTE trial, which demonstrated an overall response rate of 32.7% in patients with anti-PD-1-failed melanoma.

Johnson & Johnson's VARIPULSE™ Pulsed Field Ablation Platform Receives FDA Approval for Atrial Fibrillation Treatment

The VARIPULSE™ platform, integrating pulsed field ablation (PFA) therapy with the CARTO™ 3D mapping system, has been approved by the FDA for atrial fibrillation (AFib) treatment.
The admIRE study supporting the approval demonstrated 100% acute procedural success and an 85% peak primary effectiveness rate with the VARIPULSE™ platform.

FDA Rejects Vanda's Tradipitant for Gastroparesis, Citing Insufficient Evidence

The FDA issued a Complete Response Letter for Vanda Pharmaceuticals' tradipitant, a neurokinin-1 receptor antagonist, for treating gastroparesis symptoms.
The FDA's decision was based on the need for additional studies, which Vanda argues are inconsistent with expert advice and current understanding of gastroparesis.

FDA Lifts Partial Clinical Hold on Vigil Neuroscience's VG-3927 Phase I Trial, Expands to Alzheimer's Patients

The FDA has lifted the partial clinical hold on Vigil Neuroscience's Phase I trial of VG-3927, a treatment for neurodegenerative diseases, following a complete response from the company.
Interim data from the trial indicated VG-3927's safety, tolerability, and potential for once-daily dosing, alongside a sustained decline in soluble TREM2 levels in cerebrospinal fluid.

FDA Grants Priority Review to Vimseltinib for Tenosynovial Giant Cell Tumor

The FDA has granted priority review to vimseltinib for treating tenosynovial giant cell tumor (TGCT), setting a PDUFA goal date of February 17, 2025.
Vimseltinib, a CSF1R inhibitor, demonstrated a 40% overall response rate in the MOTION phase 3 trial, significantly higher than placebo (0%).

FDA Grants Fast Track Designation to Vepdegestrant for ER+/HER2- Metastatic Breast Cancer

The FDA granted Fast Track designation to vepdegestrant for ER+/HER2- locally advanced or metastatic breast cancer after endocrine therapy.
Vepdegestrant, an oral PROTAC protein degrader, targets and degrades the estrogen receptor (ER), showing up to 97% ER degradation in preclinical models.

Reference News

[1]
FDA and EMA feedback endorses vididencel registration trial preparations - FirstWord Pharma
firstwordpharma.com · Jan 2, 2025

Enable JavaScript to run this app.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy